Previously Pfizer's animal-health business, Zoetis (ZTS -1.09%) is now making moves of its own. The company announced today that it is expanding its Lincoln, Neb., facility to add third-party manufactured products to Zoetis' own production line.
According to Zoetis, the 19,000-square-foot renovation will help to ensure a "reliable, consistent supply of quality medicines" for animals. The current plant produces several of the company's flagship products for livestock and dogs and is one of the largest internal manufacturing operations, with more than 500 workers.
"Zoetis is excited about the opportunity to expand its manufacturing footprint in Lincoln and to leverage the expertise in high-quality manufacturing that our colleagues have demonstrated in Lincoln for decades," said Lincoln site leader Michael Morgan in a statement. "The Lincoln facility is a key site in Zoetis' global manufacturing network and one of the largest suppliers of Zoetis' animal health products for the world. It has been in operation at its current location since 1961, producing 1,200 finished goods for more than 100 markets annually."
Construction is expected to begin later this summer, with expansions completed by 2015 .